This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
BMC Cancer Open Access 24 June 2019
-
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia
Molecular Cancer Open Access 19 February 2018
-
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
Blood Cancer Journal Open Access 31 July 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148–150.
Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a ten-year follow-up. Leukemia 1998; 12: 887–892.
Hugues L, Cave H, Philippe N, Pereira S, Fenaux P, Preudhomme C . Mutations of PTPN11 are rare in adult myeloid malignancies. Haematologica 2005; 90: 853–854.
Johan MF, Bowen DT, Frew ME, Goodeve AC, Wilson GA, Peake IR et al. Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2004; 124: 843–844.
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F Activating Tyrosine Kinase Mutation is an Infrequent Event in Both ‘Atypical’ Myeloproliferative Disorders and the Myelodysplastic Syndrome. Blood 2005; 106: 1207–1209.
Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379.
Tartaglia M, Niemeyer CM, Shannon KM, Loh ML . SHP-2 and myeloid malignancies. Curr Opin Hematol 2004; 11: 44–50.
Yin T, Shen R, Feng GS, Yang YC . Molecular Characterization of Specific Interactions between SHP-2 Phosphatase and JAK Tyrosine Kinases. J Biol Chem 1997; 272: 1032–1037.
Acknowledgements
This work was supported in part by grants from the National Science Council of the Republic of China NSC 93-2314-B002-038 and NSC 94-2752-B002-006-PAE, National Taiwan University Hospital NTUH 93-5051 and the Department of Medical Research in National Taiwan University Hospital, Taiwan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, CY., Lin, LI., Tang, JL. et al. Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 20, 1155–1158 (2006). https://doi.org/10.1038/sj.leu.2404190
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404190
This article is cited by
-
Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019
Annals of Hematology (2021)
-
Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
BMC Cancer (2019)
-
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia
Molecular Cancer (2018)
-
Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults
BMC Cancer (2015)
-
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
Blood Cancer Journal (2015)